Request Demo
Last update 27 Dec 2024
Pittsburgh Compound B
Last update 27 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms (N-methyl-(11C))2-(4'-methylaminophenyl)-6-hydroxybenzothiazole, 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole, FSA-PIB AD + [4] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC14H12N2OS |
InChIKeyZQAQXZBSGZUUNL-BJUDXGSMSA-N |
CAS Registry566170-04-5 |
Related
37
Clinical Trials associated with Pittsburgh Compound BNCT04542603
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
NCT06439992
Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)
JPRN-UMIN000054523
Investigation of the molecular pathogenesis of cardiac amyloidosis using 18F-flutemetamol and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy. - FMM, PiB, and HMDP accumulation in cardiac amyloidosis
100 Clinical Results associated with Pittsburgh Compound B
Login to view more data
100 Translational Medicine associated with Pittsburgh Compound B
Login to view more data
100 Patents (Medical) associated with Pittsburgh Compound B
Login to view more data
178
Literatures (Medical) associated with Pittsburgh Compound B01 Sep 2024Current radiopharmaceuticals
Automated Synthesis of [11C]PiB via [11CH3OTf]-as Methylating Agent for
PET Imaging of β-Amyloid
Article
Author: Dixit, Manish ; Singh, Akhilesh K. ; Gambhir, Sanjay
Aim:::
Efficient synthesis of precursor from commercially available starting materials
and automated radiosynthesis of [11C]PiB using commercially available dedicated [11C]-
Chemistry module from the synthesized precursor.
Background:::
[11C]PiB is a promising radiotracer for PET imaging of β-Amyloid,
advancing Alzheimer's disease research. The availability of precursors and protocols
for efficient radiolabelling foster the applications of any radiotracer. Efficient synthesis
of PiB precursor was performed using anisidine and 4-nitrobenzoyl chloride as starting
materials in 5 steps, having addition, substitutions, and cyclization chemical methodologies.
This precursor was used for fully automated radiosynthesis of [11C]PiB in a commercially
available synthesizer, MPS-100 (SHI, Japan). The synthesized [11C]PiB was purified via
solid-phase methodology, and its quality control was performed by the quality and safety criteria
required for clinical use.
Methods:::
The synthesis of desired precursors and standard authentic compounds started
with commercially available materials with 70-80% yields. The standard analytical methods
were characterized all synthesized compounds. The fully automated [11C]-chemistry synthesizer
(MPS-100) used for radiosynthesis of [11C]PiB with [11C]CH3OTf acts as a methylating agent.
For radiolabelling, varied amounts of precursor and time of reaction were explored. The resulting
crude product underwent purification through solid-phase cartridges. The synthesized radiotracer
was analyzed using analytical tools such as radio TLC, HPLC, pH endo-toxicity, and
half-life.
Results:::
The precursor for radiosynthesis of [11C]PiB was achieved in excellent yield using
simple and feasible chemistry. A protocol for radiolabelling of precursor to synthesized
[11C]PiB was developed using an automated synthesizer. The crude radiotracer was purified by
solid-phase cartridge, with a decay-corrected radiochemical yield of 40±5% and radiochemical
purity of more than 97% in approx 20 minutes (EOB). The specific activity was calculated and
found in a 110-121 mCi/μmol range.
Conclusion:::
A reliable methodology was developed for preparing precursor followed by
fully automated radiolabeling using [11C]MeOTf as a methylating agent to synthesize
[11C]PiB. The final HPLC-free purification yielded more than 97% radiochemical purity
tracer within one radionuclide half-life. The method was reproducible and efficient for any
clinical center.
09 Aug 2024ORGANIC LETTERS
Utilization of a Branched Late-Stage Clickable Biotinylated Chassis on the Example of a Pittsburgh B Analogue
Article
Author: Weber, T Moritz ; Özdüzenciler, Pelin ; Tamgüney, Gültekin ; Pietruszka, Jörg
Biotinylation is probably the most frequent and practically useful modification of molecules to facilitate selective and highly affine binding to (strept)avidin for immobilization, enrichment, and purification for further (bio)chemical or (bio)physical investigations. We present a protecting-group-free synthesis of a branched biotin bis-azide that enables dual-payload late-stage functionalization with arbitrary alkynes via click chemistry. Utility of the chassis is briefly showcased on the example of a valuable Pittsburgh B analogue, which binds pathological protein aggregates, commonly found in neurodegenerative diseases.
06 Aug 2024ACS Omega
Light Activated Release of Nitrile Ligands from trans-Ru(L)(PPh3)2(nitrile) Complexes
Article
Author: Yufit, Dmitry S. ; Hsu, Yu-Ting ; Beeby, Andrew ; Davidson, Ross J.
A series of trans-RuL(PPh3)2(nitrile) and {RuL(PPh3)2}.2-μ-(nitrile)-based complexes [where L = 2,2'-(3,4-diphenyl-pyrrole-2,5-diyl)dipyridine (dpp), di(pyridin-2-yl)isoindoline-1,3-diimine (bpi), or 4-(4-methoxyphenyl)-6-phenyl-2,2'-bipyridine (Pbpy); and nitrile = 1,4-dibenzontirile, 4-ethynylbenzonitrile, or dicyanamide] were synthesized and characterized, and their electrochemical and photochemical behaviors were investigated. Those complexes that contained a significant nitrile contribution to their 3MLLCT show a release of their nitrile ligand (when L = dpp or Pbpy and the nitrile ligand = 4-dibenzontirile, or 4-ethynylbenzonitrile) with dissociation constants up to 8.09 × 10-4 s-1.
100 Deals associated with Pittsburgh Compound B
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Pittsburgh Compound B | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis | Phase 2 | US | 10 Jul 2023 | |
| Alzheimer Disease | Phase 2 | US | 01 Mar 2009 | |
| Alcohol Use Disorder | Phase 1 | US | 01 Dec 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 13 | zdhrahlwnu(zldbonliln) = etenwobxfl wenihyokyq (inaiafirkd, nggziuuuqo - kdeeduyquz) View more | - | 01 May 2024 | |||
zdhrahlwnu(zldbonliln) = gkdkorrflx wenihyokyq (inaiafirkd, hkskktcaru - tlcoiujezv) View more | |||||||
Not Applicable | HOMA-IR | APOEε4+ | 60 | (Insulin resistance group (IR+)) | vogekrlgtc(xqpxtffaqu) = akroqkazty xhizzhrfgs (iokbgrbydv ) View more | - | 16 Jun 2023 | |
(Control group (IR-)) | vogekrlgtc(xqpxtffaqu) = rnykbdluvl xhizzhrfgs (iokbgrbydv ) | ||||||
Not Applicable | APOE ε4 | 23 | (Amyloid-negative individuals) | wqmalnpjkb(ijiiaegezg) = cdxnxjlgkv loqsxwbqud (ryaclsnzrj ) | - | 07 Dec 2020 | |
Not Applicable | - | 11C- and 18F- tracers (MS patients) | zgwwknnqtr(rtuhbovsgj) = hrswvpjwjm dvuqwamozg (sjbbqqlgni, 0.19) | - | 10 Sep 2019 | ||
11C- and 18F- tracers (Healthy controls) | zgwwknnqtr(rtuhbovsgj) = jsdeoasrya dvuqwamozg (sjbbqqlgni, 0.21) | ||||||
Not Applicable | - | - | ihtwoiacwa(sxdwwdqcym) = bwnofughun lhwbrurocy (pdthnxnqcd ) | - | 21 May 2019 | ||
Not Applicable | - | 4 | vcidfvhboi(ocyhkiaorr) = eeutmfixbm xsutciqfpq (zihajtyxuu, 0.20) | - | 23 May 2018 | ||
vcidfvhboi(ocyhkiaorr) = tdinawfgjz xsutciqfpq (zihajtyxuu, 0.10) | |||||||
Phase 2 | 89 | (Alzheimer's Disease) | fxwqrhcddm(alnwluwafw) = qcvmmtuytj uznsquwoji (zgmfzhqrch, ietdjfwvkr - uoatnflrws) View more | - | 01 Nov 2016 | ||
(Cognitive Normal Elderly) | fxwqrhcddm(alnwluwafw) = jbfchllsqh uznsquwoji (zgmfzhqrch, oynzduwbvj - zwwtithfok) View more | ||||||
Not Applicable | 72 | (Hypertensive patients with cognitive concerns or MCI) | esntdkfbhp(jkpxdivray) = ntmvywvjxq qrgulswuyp (uxmezokrqt, 0.11 - 0.64) View more | - | 01 Jul 2013 | ||
Not Applicable | - | tedllhocpk(ynphwjjqau) = xgtshthnax tnmhwxvzeb (zdseqpuzfm ) | - | 01 Jul 2013 | |||
tedllhocpk(ynphwjjqau) = rxpcfhxlsh tnmhwxvzeb (zdseqpuzfm ) | |||||||
Not Applicable | Dementia beta-amyloid | - | wdrkkuyamz(emvepzmakz) = hhmvzpcjpg mrqnquawqy (pzgmhjbkrk ) View more | - | 01 Jul 2012 | ||
18F-AZD4694 | wdrkkuyamz(emvepzmakz) = movqapxfpn mrqnquawqy (pzgmhjbkrk ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free